Nimbolide, a terpenoid natural product derived from the Neem tree, impairs cancer pathogenicity across many types of human cancers; however, the direct targets and mechanisms by which nimbolide exerts its effects are poorly understood. Here, we used activity-based protein profiling (ABPP) chemoproteomic platforms to discover that nimbolide reacts with a novel functional cysteine crucial for substrate recognition in the E3 ubiquitin ligase RNF114. Nimbolide impairs breast cancer cell proliferation by disrupting RNF114 substrate recognition, leading to inhibition of ubiquitination and degradation of the tumor-suppressor p21, resulting in its rapid stabilization. We further demonstrate that nimbolide can be harnessed to recruit RNF114 as an E3 ligase in targeted protein degradation applications and show that synthetically simpler scaffolds are also capable of accessing this unique reactive site. Our study highlights the utility of ABPP platforms in uncovering unique druggable modalities accessed by natural products for cancer therapy and drug discovery applications.
Introduction
Natural products from organisms such as plants and microbes are a rich source of therapeutic lead compounds [1] [2] [3] [4] [5] . The characterization of their biological activities has resulted in myriad medications for disparate pathologies such as cancer, bacterial and fungal infections, inflammation, and diabetes [1] [2] [3] [4] [5] . Among natural products there exists a subset of covalently acting molecules that bear electrophilic moieties capable of undergoing essentially irreversible reactions with nucleophilic amino acid hotspots within proteins to exert their therapeutic activity. Examples of these natural products include penicillin, which irreversibly inhibits serine transpeptidases inducing anti-bacterial activity, or wortmannin, which covalently modifies a functional lysine on PI3-kinase to inhibit its activity [5] [6] [7] . Discovering druggable hotspots targeted by anti-cancer and covalentlyacting natural products can not only yield new cancer drugs and therapeutic targets but can also reveal unique insights into modalities accessed by natural products in protein targets that are often considered undruggable or difficult to tackle with standard drug discovery efforts. One example of a druggable modality that would be difficult to predict a priori is FK506 or Tacrolimus that inhibits peptidylprolyl isomerase activity by binding to FKBP12 thus creating a FKBP12-FK506 complex that modulates T cell signaling via inhibition of calcineurin 8 .
Gaining insights into nature's strategies for engaging protein targets can thus provide access to new
perspectives on what may be considered druggable.
In this study, we investigated the mechanism of action of the natural product nimbolide, a limonoid natural product derived from the Neem tree (Azadirachta indica) ( Figure 1A ) 9 . Nimbolide has been shown to exert multiple therapeutic effects and possesses a cyclic enone capable of reacting with cysteines [10] [11] [12] . In the context of cancer, nimbolide has been shown to inhibit tumorigenesis and metastasis without causing any toxicity or unwanted side effects across a wide range of cancers 10, 11, [13] [14] [15] [16] [17] . While previous studies suggest that nimbolide impairs cancer pathogenicity through modulating signaling pathways and transcription factors linked to survival, growth, invasion, angiogenesis, inflammation, and oxidative stress the direct targets of nimbolide still remain poorly characterized 10, 15, [18] [19] [20] [21] [22] .
Identifying direct protein targets of complex natural products remains challenging and often requires synthesizing analogs of these compounds bearing photoaffinity and enrichment handles, a task which is synthetically challenging and has the potential to alter the activity of the molecule [23] [24] [25] . Even with the generation of such probes, identifying the specific amino acid site targeted by natural products is challenging.
In this study, we utilized activity-based protein profiling (ABPP) chemoproteomic approaches to map the proteome-wide targets of nimbolide in breast cancer cell proteomes. Using ABPP platforms, we reveal that one of the primary targets of nimbolide in breast cancer cells is cysteine-8 (C8) of the E3 ubiquitin ligase RNF114.
Covalent modification of RNF114 by nimbolide leads to impaired ubiquitination and degradation of its substrate-the tumor suppressor p21-leading to its rapid stabilization. Intriguingly, we show that this apparent inhibition of RNF114 activity is through impaired substrate recognition giving rise to the possibility that nimbolide could be used as an E3 ligase recruitment module for targeted protein degradation. Strategies for chemically induced degradation of targets of interest in cells is rapidly gaining interest in drug discovery, including the development of bifunctional molecules referred to as "proteolysis-targeting chimeras"
(PROTACs) or "heterobifunctional degraders" that consist of a protein-targeting ligand linked to an E3 ligase recruiter to bring an E3 ligase to a protein of interest to ubiquitinate and mark the target for degradation in a proteasome-dependent manner [26] [27] [28] [29] [30] [31] [32] [33] [34] . We demonstrate that nimbolide can be used to recruit RNF114 to other protein substrates for targeted protein degradation applications. Using chemoproteomics-enabled covalent ligand screening platforms, we also identify more synthetically tractable compounds that can similarly react with C8 of RNF114 and phenocopy nimbolide action.
Results

Effects of nimbolide on breast cancer cell survival and proliferation
Though nimbolide has been shown to impair cancer pathogenicity across many different types of human cancers, we chose to focus on elucidating the role of nimbolide in triple-negative breast cancers (TNBC). TNBCs are devoid of estrogen, progesterone, and HER2 receptors and are amongst the most aggressive cancers with the worst clinical prognosis 35, 36 . Very few targeted therapies currently exist for TNBC patients. Uncovering new therapeutic modalities in TNBCs would thus potentially contribute significantly to reducing breast cancer-associated mortalities. Consistent with previous reports showing anti-cancer activity in breast cancer cells, nimbolide impaired cell proliferation or serum-free cell survival in 231MFP and HCC38
TNBC cells ( Figure 1B ) 14, 15, 17 .
Using ABPP platforms to map druggable hotspots targeted by nimbolide in breast cancer cells
To interrogate the mechanisms by which nimbolide impairs breast cancer pathogenicity, we applied a chemoproteomic platform termed isotopic tandem orthogonal proteolysis-enabled activity-based protein profiling (isoTOP-ABPP) to determine the specific protein targets of nimbolide. Pioneered by Cravatt and Weerapana, isoTOP-ABPP uses reactivity-based chemical probes to map reactive, functional, and druggable hotspots directly in complex proteomes [37] [38] [39] [40] . When used in a competitive manner, covalently-acting smallmolecules can be competed against reactivity-based probe binding to facilitate target identification [40] [41] [42] [43] [44] [45] [46] [47] ( Figure   2A ). In this study, we treated breast cancer cells in situ with vehicle or nimbolide followed by competitive labeling of proteomes with a cysteine-reactive alkyne-functionalized iodoacetamide probe (IA-alkyne), after which isotopically light or heavy cleavable enrichment handles were appended to probe-labeled proteins for isoTOP-ABPP analysis. Probe-modified tryptic peptides were analyzed by liquid chromatography-mass spectrometry (LC-MS/MS) and light to heavy tryptic probe-modified peptide ratios, representing control versus treated IA-alkyne labeled sites, were quantified. IsoTOP-ABPP analysis of ligandable hotspots targeted by in situ nimbolide treatment in 231MFP TNBC cells showed two targets showing isotopic ratios >4-namely RNF114 and HPCAL1 ( Figure 2B ; Table S1 ). Importantly, RNF114 knockdown using RNA interference closely resembled the anti-proliferative effects of nimbolide in 231MFP cells, indicating that RNF114 is likely to constitute the primary efficacy target of nimbolide ( Figure 2C ). Further supporting this hypothesis, RNF114
was the target responsible for nimbolide action, RNF114 knockdown led to significantly heightened sensitivity to nimbolide-mediated anti-proliferative effects ( Figure 2D ). We thus chose to focus further characterization efforts upon RNF114.
Biochemical characterization of nimbolide interactions with RNF114
RNF114 is an E3 ubiquitin ligase of the RING family 48, 49 . The site on RNF114 identified by isoTOP-ABPP as the target of nimbolide, C8, falls within the N-terminal region of the protein, predicted to be intrinsically disordered, and resides outside of the two annotated zinc finger domains ( Figure 3A) . Intrigued by the apparent selective targeting of an intrinsically disordered region of a protein by a natural product, we sought to investigate the interaction between nimbolide and RNF114.
Because isoTOP-ABPP is a competitive assay between the covalently-acting molecule and a broader reactive probe, it is an indirect read-out of potential nimbolide-targeting hotspots. To confirm that nimbolide directly targeted RNF114, we synthesized the alkyne-functionalized probe shown in three steps from nimbolide ( Figure 3B) . Selective bromination at C2 of the furan moiety and subsequent Suzuki coupling with 4-Formylphenylboronic acid afforded the aryl-aldehyde 2, which was converted to its corresponding carboxylic acid (3) via Pinnick oxidation. Finally, coupling of 3 and propargyl amine (HATU, DIPEA) afforded the target probe. We confirmed that this nimbolide probe reacts with pure human RNF114 protein. This labeling event was also competed by nimbolide and abrogated in the C8A RNF114 mutant ( Figure 3C ). Furthermore, a direct mass adduct of nimbolide on C8 of RNF114 was observed by LC-MS/MS after incubation of pure protein with the natural product ( Figure 3D ). Taken together, these findings provide convincing evidence that nimbolide modifies an intrinsically disordered region of RNF114 at C8 through a covalent bond formation.
Effects of nimbolide on RNF114 activity and substrate binding in vitro and in situ
RNF114 has been previously shown to ubiquitinate and degrade the tumor suppressor p21, among other substrates 48, 50, 51 . In an in vitro reconstituted system, nimbolide inhibited both RNF114 autoubiquitination and p21 ubiquitination activity ( Figure 4A ). The RNF114 C8A mutation did not affect basal RNF114 autoubiquitination activity, but attenuated the inhibition observed with nimbolide treatment ( Figure 4B ).
Previous characterization of RNF114 suggested that the N-terminus may be involved in substrate recognition 48 . Consistent with this premise, we found that the amount of p21 co-immunoprecipitated with RNF114 was reduced by nimbolide, suggesting that the apparent inhibition of RNF114 may be due to impaired substrate recognition, rather than inhibition of its catalytic activity ( Figure 4C ). We further demonstrated that nimbolide treatment in 231MFP cells stabilized p21 protein expression within 1 hour, with no significant changes to p53 levels ( Figure 4D, Figure S1 ). Collectively, this data suggests that nimbolide reacts with an intrinsically disordered C8 of RNF114 to disrupt RNF114-p21 substrate recognition, leading to inhibition of p21 ubiquitination, rapid p21 stabilization, and impaired cell proliferation in breast cancer cells.
Using nimbolide as an RNF114-recruiter for targeted protein degradation
Since nimbolide targets a potential substrate recognition site, we conjectured that nimbolide could be used to recruit RNF114 to other protein substrates for proteasomal degradation through the development of bifunctional degraders using nimbolide as an RNF114 recruiter. To demonstrate feasibility, two degraders formed by linking nimbolide to the Bromodomain and extra-terminal (BET) family inhibitor JQ1 were synthesized ( Figure 5A; Figure S2A ). Prior studies have demonstrated efficient proteasome-dependent degradation of BET family members and in particular BRD 4 with JQ1-based degraders linked to either a cereblon-recruiter thalidomide or a VHL recruiter 27, 30, 34 . Previously prepared acid 3 was coupled to JQ1-functionalized amines containing both longer (PEG-based) and shorter (alkyl-based) spacer units, arriving at degraders XH1 and XH2 ( Figure 5A ; Figure S2A ). While XH1 did not show appreciable BRD4 degradation, XH2 treatment in 231MFP cells led to BRD4 degradation after a 12 h, but not 8 h treatment ( Figure 5B ; Figure   S2B , 8 h data not shown). Comparing the dose-response of BRD4 degradation between XH2 to a previously reported JQ1-based degrader MZ1 that utilizes a VHL recruiter, we showed that XH2 showed better BRD4 degradation compared to MZ1 at 10 nM, but MZ1 showed better BRD4 degradation at 1 and 0.1 µM compared to XH2 ( Figure 5B ). Interestingly, XH2 showed less degradation at 1 µM compared to 0.1 and 0.01 µM and MZ1 showed less degradation at 20 µM compared to 10, 1, and 0.1 µM, which we attribute to the "hook effect"
previously reported with degraders including MZ1 26, 27 . To confirm proteasome-dependence of BRD4 degradation, we showed that the XH2-mediated degradation of BRD4 was attenuated by pre-treatment of cells with the proteasome inhibitor bortezomib (BTZ) ( Figure 5C ). XH2-mediated BRD4 degradation was also prevented by pre-treatment with an E1 ubiquitin-activating enzyme inhibitor (TAK-243) or pre-competing with the BRD4 inhibitor JQ1 ( Figure 5D , Figure S2C ). However, treatment with a translation inhibitor (emetine) had no effect of the observed degradation of BRD4 ( Figure S2D ). To further demonstrate that the degradation of BRD4 by XH2 was through the specific recruitment of RNF114, we showed that degradation of BRD4 by XH2, but not MZ1, was not observed in RNF114 knockout (KO) HAP1 cells compared to wild-type (WT) HAP1 cell counterparts ( Figure 5E ). The selectivity of XH2-mediated degradation of proteins was demonstrated using tandem mass tagging (TMT)-based quantitative proteomic profiling experiment to assess changes in protein expression. We showed that XH2 selectively degrades BRD4 in 231MFP breast cancer cells while sparing the other identified BET family members BRD 2 and 3 ( Figure 5F ). Of note, we also observed several proteins that showed increased levels upon XH2 treatment--including p21 (CDKN1A) which we had observed previously with nimbolide treatment alone. These upregulated proteins may be potential substrates of RNF114 with stabilization stemming from the nimbolide portion of XH2 or downstream transcriptional effects stemming from JQ1-mediated BRD4 inhibition and degradation. If these proteins were RNF114 substrates, we would expect these proteins to be elevated with nimbolide treatment alone. We thus performed a TMT-based quantitative proteomic experiment on 231MFP cells treated with nimbolide. Consistent with our premise, protein levels of several of the targets upregulated with XH2 treatment were also increased with nimbolide treatment alone, including CDKN1C, CDKN1A, PEG10, and CTGF. Beyond CDKN1A (p21) and CDKN1C (p57) which have previously been reported as potential RNF114 substrates 48 , PEG10 and CTGF may represent additional novel substrates of RNF114 ( Figure 5G ). Our results strongly suggest that nimbolide reactivity with C8 of RNF114
can be exploited to recruit this E3 ligase to other protein substrates, such as BRD4, to ubiquitinate and selectively degrade them.
Chemoproteomics-enabled covalent ligand screening to identifying covalent ligands against RNF114
With the insight gained that C8 of RNF114 has potential to be exploited for cancer therapy and targeted protein degradation applications, we searched for more synthetically tractable covalent ligands that similarly target RNF114. To achieve this goal, we screened a library of cysteine-reactive covalent ligands against While EN62 requires further improvements to potency, this covalent ligand represents a more synthetically tractable starting point for future cancer therapy and protein degradation applications.
Discussion
Collectively, we show compelling evidence that nimbolide impairs breast cancer pathogenicity in-part through targeting a substrate recognition domain at C8 within RNF114 to inhibit p21 ubiquitination and degradation, leading to its stabilization. We demonstrate that nimbolide targeting of C8 on RNF114 can be used to recruit RNF114 for targeted protein degradation applications and degradation of BRD4 with a nimbolide-JQ1 degrader XH2 is possible. Additionally, using chemoproteomics-enabled covalent ligand screening approaches, we show proof-of-concept that more synthetically tractable covalent ligands, such as EN62, can be rapidly identified to target druggable sites employed by complex natural products, such as C8 of RNF114.
We report here that nimbolide disrupts RNF114 interactions with one of its endogenous substrate p21
and we also show that p21 levels are rapidly stabilized in breast cancer cells in a p53-independent manner.
Several other E3 ligases have also been reported to degrade p21, including SCF Skp2 , CRL4 Cdt2 , and CHIP under varying conditions during cell cycle or exogenous stress [52] [53] [54] . Previous studies have shown that RNF114
expression is elevated at late G1 phase to regulate p21 levels and is crucial for G1-to-S phase transition 48 .
Other RNF114 substrates that have been reported include TAB1 involved in maternal-to-zygotic transition and A20 involved in NF-kB activity and T cell activation 55, 56 . In cancer contexts or other cell and tissue types, nimbolide may thus have additional activities through regulating the levels of other RNF114 protein substrates.
Intriguingly, we show several proteins heightened in expression with XH2 treatment, including previously reported RNF114 substrates p21 (CDKN1A) and p57 (CDKN1C), as well as several other proteins ( Figure 5F ).
These proteins may represent additional substrates of RNF114. Consistent with this premise, we also observe p21, p57, and CTGF and PEG10 levels heightened with nimbolide treatment alone ( Figure 5G ). Further studies are required to establish these additional proteins as direct substrates of RNF114. Furthermore, while we show that RNF114 is one of the primary functional targets of nimbolide, there may be additional protein targets that may not have been readily identified using this method due to reversibility or IA-probe limitations.
Nonetheless, we demonstrate that RNF114 is an important and functional target of nimbolide in breast cancer cell proliferation, since knockdown of RNF114 hypersensitized the cells to nimbolide.
Our results also demonstrate that nimbolide functionally targets an intrinsically disordered region within RNF114. Solving the structure of RNF114 covalently modified with nimbolide has thus far proven challenging, but future studies investigating whether nimbolide induces order in the N-terminus would provide insights into the ligandability of intrinsically disordered and undruggable protein targets and strategies for potentially targeting other E3 ligases.
Targeted protein degradation has emerged as a formidable and effective drug discovery paradigm for targeting proteins for elimination through the proteasome 26, 28 Interestingly, we did not observe degradation of BRD2 and 3 under conditions that led to significant reduction of BRD4 levels despite the high homology in their respective BET bromodomains. Various levels of selectivity within the BET family members and the structural basis thereof have been reported for JQ1-based degraders with Cereblon and VHL-recruiting modules 27, 30, 61, 62 . While a more detailed investigation of the selectivity of XH2 and its structural basis is outside the scope of this study, it serves as another example how availability of additional E3-moieties for a given substrate recognition modules can aid in tuning efficacy and selectivity of degraders targeting a given protein of interest.
Overall, our study further demonstrates the utility of using ABPP-based chemoproteomic platforms to identify unique druggable modalities exploited by natural products. Intriguingly, we show that a natural product can functionally access an E3 ligase protein-protein interaction site for potential cancer therapy and targeted protein degradation applications and remarkably does so in an intrinsically disordered region of the protein.
Our study also showcases how covalent ligand screening approaches can be utilized to identify more synthetically tractable small-molecules that act similarly to more complex natural products and that covalent ligands may be able to access other E3 ligases to expand the scope of E3 ligase recruiters.
Methods
Cell Culture
The 231MFP cells were obtained from Prof. Benjamin Cravatt and were generated from explanted tumor xenografts of MDA-MB-231 cells as previously described 63 . HCC38 and HEK293T cells were obtained from the American Type Culture Collection. HEK293T cells were cultured in DMEM containing 10% (v/v) fetal bovine serum (FBS) and maintained at 37°C with 5% CO2. 231MFP were cultured in L15 medium containing 10% FBS and maintained at 37°C with 0% CO2. HCC38 cells were cultured in RPMI medium containing 10%
FBS and maintained at 37°C with 5% CO2. HAP1 RNF114 wild-type and knockout cell lines were purchased from Horizon Discovery. The RNF114 knockout cell line was generated by CRISPR/Cas9 to contain a frameshift mutation in a coding exon of RNF114. HAP1 cells were grown in Iscove's Modified Dulbecco's Medium (IMDM) in the presence of 10 % FBS and penicillin/streptomycin.
Survival and Proliferation Assays
Cell survival and proliferation assays were performed as previously described using Hoechst 33342 dye (Invitrogen) according to manufacturer's protocol and as previously described 64 . 231MFP cells were seeded into 96-well plates (40,000 for survival and 20,000 for proliferation) in a volume of 150 μl and allowed to adhere overnight. Cells were treated with an additional 50 μL of media containing 1:250 dilution of 1000 x compound stock in DMSO. After the appropriate incubation period, media was removed from each well and 100 μl of staining solution containing 10% formalin and Hoechst 33342 dye was added to each well and incubated for 15 min in the dark at room temperature. After incubation, staining solution was removed, and wells were washed with PBS before imaging. Studies with HCC38 cells were also performed as above but were seeded with 20,000 cells for survival and 10,000 cells for proliferation.
IsoTOP-ABPP chemoproteomic studies
IsoTOP-ABPP studies were done as previously reported 37, 40, 44, 65 . Cells were lysed by probe sonication in PBS and protein concentrations were measured by BCA assay 66 
Mass Spectrometry Analysis
Peptides from all chemoproteomic experiments were pressure-loaded onto a 250 μm inner diameter fused silica capillary tubing packed with 4 cm of Aqua C18 reverse-phase resin (Phenomenex # 04A-4299) which was previously equilibrated on an Agilent 600 series HPLC using gradient from 100% buffer A to 100% buffer B over 10 min, followed by a 5 min wash with 100% buffer B and a 5 min wash with 100% buffer A. The samples were then attached using a MicroTee PEEK 360 μm fitting (Thermo Fisher Scientific #p-888) to a 13 cm laser pulled column packed with 10 cm Aqua C18 reverse-phase resin and 3 cm of strong-cation exchange resin for isoTOP-ABPP studies. Samples were analyzed using an Q Exactive Plus mass spectrometer (Thermo Fisher Scientific) using a 5-step Multidimensional Protein Identification Technology (MudPIT) program, using 0 %, 25 %, 50 %, 80 %, and 100 % salt bumps of 500 mM aqueous ammonium acetate and using a gradient of 67 . Cysteine residues were searched with a static modification for carboxyaminomethylation (+57.02146) and up to two differential modifications for methionine oxidation and either the light or heavy TEV tags (+464.28596 or +470.29977, respectively). Peptides were required to have at least one tryptic end and to contain the TEV modification. ProLUCID data was filtered through DTASelect to achieve a peptide false-positive rate below 5%. Only those probe-modified peptides that were evident across all two out of three biological replicates were interpreted for their isotopic light to heavy ratios. Those probemodified peptides that showed ratios >3 were further analyzed as potential targets of the covalently-acting small-molecule. For modified peptides with ratios >3, we filtered these hits for peptides were present in all three biological replicates. For those probe-modified peptide ratios >3, only those peptides with 3 ratios >3
were interpreted, and otherwise replaced with the lowest ratio. For those probe-modified peptide ratios >4, only those peptides with 3 ratios >4 were interpreted, and otherwise replaced with the lowest ratio. MS1 peak shapes of any resulting probe-modified peptides with ratios >3 were then manually confirmed to be of good quality for interpreted peptides across all biological replicates.
Constructing knockdown lines
We used short-hairpin oligonucleotides to knock down the expression of RNF114 in 231MFP cells using previously described methods 68 . For generation of stable shRNA lines, lentiviral plasmids in the pLKO.1 backbone containing shRNA (Sigma) against human RNF114 were transfected into HEK293T cells using Lipofectamine (Invitrogen). Lentivirus was collected from filtered cultured medium and used to infect the target cancer cell line with Polybrene. Target cells were selected over 3 days with 1 μg/ml puromycin. The shorthairpin sequence used for generation of the RNF114 knockdown lines was:
MISSION shRNA Bacterial Glycerol Stock, TRCN0000314877).
The control shRNA was targeted against GFP with the target sequence GCAAGCTGACCCTGAAGTTCAT.
Knockdown was confirmed by qPCR.
Gene Expression by qPCR
Gene expression was confirmed by qPCR using the manufacturer's protocol for Fisher Maxima SYBR Green. ethanol for 2 hrs. Inhibition of target labeling was assessed by densitometry using ImageJ.
Synthesis and characterization of the nimbolide-alkyne probe and PROTACS XH1 and XH2
See supporting information for experimental details.
Synthesis and characterization of JNS27
Covalent Ligand Library
The synthesis and characterization of most of the covalent ligands screened against RNF114 have been previously reported 40 
Expression and purification of wild-type and C8A RNF114
RNF114 was expressed and purified using several methods. In each case, RNF114 activity and sensitivity to nimbolide was confirmed. For the first method, we purchased wild-type mammalian expression plasmids with C-terminal FLAG tag were purchased from Origene (Origene Technologies Inc., RC209752). The RNF114
C8A mutant was generated with Q5 site-directed mutagenesis kit according to manufacturer's instructions (New England Biolabs, E0554S). Expression and purification conditions were optimized as reported previously 78 . HEK293T cells were grown to 60% confluency in DMEM (Corning) supplemented with 10 % FBS (Corning) and 2 mM L-glutamine (Life Technologies) and maintained at 37 °C with 5% CO2. Immediately prior to transfection, media was replaced with DMEM containing 5 % FBS. Each plate was transfected with 20 μg of overexpression plasmid with 100 μg PEI (Sigma). After 48 h cells were collected in TBS, lysed by sonication, and batch bound with anti-DYKDDDDK resin (GenScript, L00432) for 90 min. Lysate and resin was loaded onto a gravity flow column and washed, followed by elution with 250 ng/μL 3 x FLAG peptide (ApexBio, A6001). Purity and concentration were verified by PAGE, UV/Spectroscopy, and BCA assay.
LC-MS/MS analysis of RNF114
Purified RNF114 ( 
RNF114 ubiquitination assay
Recombinant Myc-Flag-RNF114 proteins were either purified from HEK292T cells as described above or The mixture was incubated at 37 °C with agitation for 1.5 h. 20 μL of Laemmli's buffer was added to quench the reaction and proteins were analyzed by western blot assay.
RNF114/p21 pulldown
Recombinant Flag-tagged RNF114 was used as bait to precipitate pure recombinant p21 (Origene Technologies Inc., TP309752 and TP720567) using Anti-Flag agarose beads (GenScript Biotech Corp., L00432). One microgram of Flag-RNF114 was added to 50 μL of TBS, followed by the addition of nimbolide (100 μM final concentration, Cayman Chemical Co., 19230) or equivalent volume of DMSO. Samples were incubated at room temperature for 30 min. One microgram of pure p21 was added to each sample, and samples were incubated at room temperature 30 min with agitation. Ten microliters of Flag agarose beads were added to each sample, and samples were agitated at room temperature for 30 min. Washes (3 times, 1 mL TBS) were performed before proteins were eluted using 50 μL of TBS supplemented with 250 ng/μL 3 x FLAG peptide (ApexBio A6001). Supernatant (30 μL) were collected and after the addition of Laemmli's reducing agent (10 μL), samples were boiled at 95 °C for 5 min and allowed to cool. Samples were analyzed by Western blotting as described above.
TMT-based quantitative proteomic profiling.
Cell Lysis, Proteolysis and Isobaric Labeling. Treated cell-pellets were lysed and digested using the commercially available Pierce™ Mass Spec Sample Prep Kit for Cultured Cells (Thermo Fisher Scientific, P/N 84840) following manufacturer's instructions. Briefly, 100 µg protein from each sample was reduced, alkylated, and digested overnight using a combination of Endoproteinase Lys-C and trypsin proteases. Individual samples were then labeled with isobaric tags using commercially available Tandem Mass Tag™ 6-plex (TMTsixplex™) (Thermo Fisher Scientific, P/N 90061) or TMT11plex (TMT11plex™) isobaric labeling reagent (Thermo Fisher Scientific, P/N 23275) kits, in accordance with manufacturer's protocols.
High pH Reversed Phase Separation. Tandem mass tag labeled (TMT) samples were then consolidated, and separated using high-pH reversed phase chromatography (RP-10) with fraction collection as previously MS scans were acquired at 60,000 mass resolution (R) at m/z 400, using a target value of 4 x 10 5 ions, and a maximum fill time of 50 ms. MS 2 scans were acquired as CID ion trap (IT) rapid type scans using a target value of 1 x 10 4 ions, maximum fill time of 50 ms, and an isolation window of 2 Da. Data-dependent MS 3 spectra were acquired as Orbitrap (OT) scans, using Top 10 MS 2 daughter selection, automatic gain control (AGC) target of 5 x 10 4 ions, with scan range of m/z 100-500. The MS 3 maximum injection time was 86 ms, with HCD collision energy set to 65%. MS 3 mass resolution (R) was set to 15,000 at m/z 400 for TMT6plex experiments, and 50,000
at m/z 400 for TMT11-plex experiments. Dynamic exclusion was set to exclude selected precursors for 60 s with a repeat count of 1. Nanospray voltage was set to 2.2 kV, with heated capillary temperature set to 300 ºC, and an S-lens RF level equal to 30%. No sheath or auxiliary gas flow is applied.
Data Processing and Analysis. Acquired MS data was processed using Proteome Discoverer v. Reporter ion ratio calculations were performed using summed abundances with most confident centroid selected from 20 ppm window. Only peptide-to-spectrum matches that are unique assignments to a given identified protein within the total dataset are considered for protein quantitation. High confidence protein identifications were reported using a Percolator estimated <1% false discovery rate (FDR) cut-off. Differential abundance significance was estimated using a backround-based ANOVA with Benjamini-Hochberg correction to determine adjusted p-values.
Tumor xenograft studies
Human tumor xenografts were established by transplanting cancer cells ectopically into the flank of female C.B17 severe combined immunodeficiency (SCID) mice (Taconic Farms) as previously described 68, 81 . In brief, cells were washed with PBS, trypsinized, and harvested in serum-containing medium. Harvested cells were washed in serum-free media and resuspended in serum-free media at a concentration of 2.0 × 10 4 cells/μl, and 100 μl was injected subcutaneously into the flank of each mouse. Tumors were measured with calipers. Animal experiments were conducted in accordance with the guidelines of the Institutional Animal Care and Use
Committees of the University of California, Berkeley.
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